"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 3 | 3 |
| 1999 | 2 | 1 | 3 |
| 2000 | 3 | 2 | 5 |
| 2001 | 2 | 5 | 7 |
| 2002 | 2 | 3 | 5 |
| 2003 | 2 | 4 | 6 |
| 2004 | 5 | 8 | 13 |
| 2005 | 3 | 2 | 5 |
| 2006 | 4 | 2 | 6 |
| 2007 | 4 | 1 | 5 |
| 2008 | 7 | 6 | 13 |
| 2009 | 3 | 2 | 5 |
| 2010 | 7 | 5 | 12 |
| 2011 | 5 | 5 | 10 |
| 2012 | 8 | 7 | 15 |
| 2013 | 7 | 9 | 16 |
| 2014 | 6 | 8 | 14 |
| 2015 | 9 | 15 | 24 |
| 2016 | 20 | 2 | 22 |
| 2017 | 22 | 3 | 25 |
| 2018 | 29 | 14 | 43 |
| 2019 | 29 | 16 | 45 |
| 2020 | 19 | 24 | 43 |
| 2021 | 22 | 19 | 41 |
| 2022 | 2 | 27 | 29 |
| 2023 | 1 | 15 | 16 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy). J Transl Med. 2023 07 28; 21(1):508.
-
YTHDF2/m6 A/NF-?B axis controls anti-tumor immunity by regulating intratumoral Tregs. EMBO J. 2023 08 01; 42(15):e113126.
-
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560.
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer. J Immunother Cancer. 2023 06; 11(6).
-
Complete response to chemoimmunotherapy with bevacizumab in synchronous multiple primary cancers: pulmonary adenocarcinoma and sarcomatoid carcinoma. Cold Spring Harb Mol Case Stud. 2023 04; 9(2).
-
Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial. Clin Cancer Res. 2023 05 01; 29(9):1698-1707.
-
Tissue-resident memory T cells in immune-related adverse events: friend or foe? Oncoimmunology. 2023; 12(1):2197358.
-
Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy. Cancer Res Commun. 2023 03; 3(3):510-520.
-
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature. 2023 03; 615(7953):697-704.
-
The EU-funded I3LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy. Clin Lung Cancer. 2023 06; 24(4):381-387.